Efficacy of a novel chewable tablet (Credelio Quattro) containing lotilaner, moxidectin, praziquantel, and pyrantel for the treatment and control of Echinococcus multilocularis and E. granulosus infections in dogs.

IF 3 2区 医学 Q1 PARASITOLOGY
Samuel Charles, Gertraut Altreuther, Xinshuo Wang, Scott Wiseman, Craig R Reinemeyer, Daniel E Snyder, Michael Ulrich, Padraig Doherty, Lisa Young
{"title":"Efficacy of a novel chewable tablet (Credelio Quattro<sup>™</sup>) containing lotilaner, moxidectin, praziquantel, and pyrantel for the treatment and control of Echinococcus multilocularis and E. granulosus infections in dogs.","authors":"Samuel Charles, Gertraut Altreuther, Xinshuo Wang, Scott Wiseman, Craig R Reinemeyer, Daniel E Snyder, Michael Ulrich, Padraig Doherty, Lisa Young","doi":"10.1186/s13071-025-06735-w","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>While generally harmless to dogs, the cestode species Echinococcus granulosus and Echinococcus multilocularis have significant zoonotic importance, causing cystic echinococcosis and alveolar echinococcosis in humans, respectively. Regular deworming is essential to treat intestinal cestode infections in dogs and to reduce environmental egg contamination and thus the subsequent zoonotic risk of infection to intermediate hosts and humans. The studies described here evaluated the efficacy of a new novel chewable tablet combination containing lotilaner, moxidectin, praziquantel and pyrantel (Credelio Quattro, Elanco Animal Health) against E. granulosus and E. multilocularis infections in dogs.</p><p><strong>Methods: </strong>Four negative-controlled, masked, randomized laboratory studies were conducted. Two studies each evaluated the efficacy of Credelio Quattro at the minimum dosages of 20.0 mg/kg lotilaner, 0.02 mg/kg moxidectin, 5.0 mg/kg praziquantel and 5.0 mg/kg pyrantel against E. granulosus (Studies 1 and 2) and E. multilocularis (Studies 3 and 4). Studies 2 and 4 also included treatment groups that received praziquantel alone or lotilaner alone, at the same minimum dosages, to assess whether lotilaner, moxidectin or pyrantel interfered with the activity of praziquantel in Credelio Quattro against these two cestode species. In Studies 1 and 3, 16 purpose-bred dogs were divided into two groups of eight, while in Studies 2 and 4, 32 dogs were divided into four groups of eight. Dogs were experimentally inoculated with protoscolices on Day - 28 for E. granulosus studies and on Day - 18 or - 20 for E. multilocularis studies. Credelio Quattro, placebo, praziquantel, or lotilaner tablets were administered orally at the lower half of the dosage range on Day 0. Efficacy was calculated based on the number of worms recovered at necropsy, 4 or 5 days post-treatment, in the treated group compared to the control.</p><p><strong>Results: </strong>Credelio Quattro was well tolerated in all dogs. Based on geometric mean worm counts, Credelio Quattro was 100% effective against both E. granulosus and E. multilocularis.</p><p><strong>Conclusions: </strong>Credelio Quattro administered once orally at the minimum dosages of 20 mg/kg of lotilaner, 0.02 mg/kg of moxidectin, 5.0 mg/kg of praziquantel and 5.0 mg/kg of pyrantel was safe and effective for the treatment and control of adult E. granulosus and E. multilocularis in dogs.</p>","PeriodicalId":19793,"journal":{"name":"Parasites & Vectors","volume":"18 1","pages":"99"},"PeriodicalIF":3.0000,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11895180/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Parasites & Vectors","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13071-025-06735-w","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PARASITOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: While generally harmless to dogs, the cestode species Echinococcus granulosus and Echinococcus multilocularis have significant zoonotic importance, causing cystic echinococcosis and alveolar echinococcosis in humans, respectively. Regular deworming is essential to treat intestinal cestode infections in dogs and to reduce environmental egg contamination and thus the subsequent zoonotic risk of infection to intermediate hosts and humans. The studies described here evaluated the efficacy of a new novel chewable tablet combination containing lotilaner, moxidectin, praziquantel and pyrantel (Credelio Quattro, Elanco Animal Health) against E. granulosus and E. multilocularis infections in dogs.

Methods: Four negative-controlled, masked, randomized laboratory studies were conducted. Two studies each evaluated the efficacy of Credelio Quattro at the minimum dosages of 20.0 mg/kg lotilaner, 0.02 mg/kg moxidectin, 5.0 mg/kg praziquantel and 5.0 mg/kg pyrantel against E. granulosus (Studies 1 and 2) and E. multilocularis (Studies 3 and 4). Studies 2 and 4 also included treatment groups that received praziquantel alone or lotilaner alone, at the same minimum dosages, to assess whether lotilaner, moxidectin or pyrantel interfered with the activity of praziquantel in Credelio Quattro against these two cestode species. In Studies 1 and 3, 16 purpose-bred dogs were divided into two groups of eight, while in Studies 2 and 4, 32 dogs were divided into four groups of eight. Dogs were experimentally inoculated with protoscolices on Day - 28 for E. granulosus studies and on Day - 18 or - 20 for E. multilocularis studies. Credelio Quattro, placebo, praziquantel, or lotilaner tablets were administered orally at the lower half of the dosage range on Day 0. Efficacy was calculated based on the number of worms recovered at necropsy, 4 or 5 days post-treatment, in the treated group compared to the control.

Results: Credelio Quattro was well tolerated in all dogs. Based on geometric mean worm counts, Credelio Quattro was 100% effective against both E. granulosus and E. multilocularis.

Conclusions: Credelio Quattro administered once orally at the minimum dosages of 20 mg/kg of lotilaner, 0.02 mg/kg of moxidectin, 5.0 mg/kg of praziquantel and 5.0 mg/kg of pyrantel was safe and effective for the treatment and control of adult E. granulosus and E. multilocularis in dogs.

一种新型咀嚼片剂(Credelio Quattro™)含有洛替拉纳、莫西丁素、吡喹酮和吡喃酮治疗和控制犬多房棘球绦虫和颗粒棘球绦虫感染的疗效。
背景:虽然通常对狗无害,但绦虫属细粒棘球绦虫和多房棘球绦虫具有重要的人畜共患性,分别在人类中引起囊性棘球绦虫病和肺泡性棘球绦虫病。定期驱虫对于治疗狗的肠囊虫感染和减少环境卵污染以及随后对中间宿主和人类的人畜共患感染风险至关重要。本文描述的研究评估了一种含有洛替拉、莫西菌素、吡喹酮和吡喃酮的新型咀嚼片组合(Credelio Quattro, Elanco Animal Health)对狗颗粒性肠杆菌和多房肠杆菌感染的疗效。方法:进行4项阴性对照、隐匿、随机实验室研究。两项研究分别评估了Credelio Quattro在最小剂量为20.0 mg/kg洛替拉、0.02 mg/kg莫西汀、5.0 mg/kg吡喹酮和5.0 mg/kg吡喃酮时对颗粒绦虫(研究1和2)和多房绦虫(研究3和4)的疗效。研究2和4还包括单独使用吡喹酮或单独使用洛替拉的治疗组,以相同的最小剂量,评估洛替拉是否有效。莫西菌素和吡喃嘧啶干扰了吡喹酮对这两种寄生蜂的活性。在研究1和3中,16只目的犬被分成两组,每组8只,而在研究2和4中,32只狗被分成四组,每组8只。实验犬在第28天接种原脊柱侧突进行颗粒棘球绦虫研究,在第18天或第20天接种多房棘球绦虫研究。在第0天口服Credelio Quattro、安慰剂、吡喹酮或洛替拉片,剂量范围的下半部分。根据治疗后4天或5天尸检时发现的蠕虫数量来计算治疗组与对照组的疗效。结果:Credelio Quattro在所有犬中耐受性良好。基于几何平均蠕虫计数,Credelio Quattro对细粒棘球绦虫和多房棘球绦虫的有效率均为100%。结论:以洛替拉20 mg/kg、莫西菌素0.02 mg/kg、吡喹酮5.0 mg/kg、吡喃嘧啶5.0 mg/kg的最小剂量口服一次,可安全有效地治疗和控制成年犬颗粒性肠裂菌和多房肠裂菌。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Parasites & Vectors
Parasites & Vectors 医学-寄生虫学
CiteScore
6.30
自引率
9.40%
发文量
433
审稿时长
1.4 months
期刊介绍: Parasites & Vectors is an open access, peer-reviewed online journal dealing with the biology of parasites, parasitic diseases, intermediate hosts, vectors and vector-borne pathogens. Manuscripts published in this journal will be available to all worldwide, with no barriers to access, immediately following acceptance. However, authors retain the copyright of their material and may use it, or distribute it, as they wish. Manuscripts on all aspects of the basic and applied biology of parasites, intermediate hosts, vectors and vector-borne pathogens will be considered. In addition to the traditional and well-established areas of science in these fields, we also aim to provide a vehicle for publication of the rapidly developing resources and technology in parasite, intermediate host and vector genomics and their impacts on biological research. We are able to publish large datasets and extensive results, frequently associated with genomic and post-genomic technologies, which are not readily accommodated in traditional journals. Manuscripts addressing broader issues, for example economics, social sciences and global climate change in relation to parasites, vectors and disease control, are also welcomed.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信